查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1403489

到 2030 年阿斯匹灵药物的市场预测：按产品、剂型、配销通路和地区进行的全球分析

Aspirin Drug Market Forecasts to 2030 - Global Analysis By Product (Ecotrin, Bufferin, Generic Aspirin and Other Products), Dosage Form, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球阿斯匹灵药品市场规模为 25 亿美元，预计到 2030 年将达到 36 亿美元，预测期内复合年增长率为 5.4%。

阿斯匹灵药品市场包括含有乙酰水杨酸的药品，俗称阿斯匹灵，是一种广泛使用的药物，具有镇痛、发炎和解热作用。阿斯匹灵属于一类非类固醇消炎剂(NSAID)，用于缓解疼痛、抑制发炎和发烧控制。此外，阿斯匹灵已被证明具有抗凝血特性，可用于预防心臟病和中风等心血管事件。

根据美国国家公共卫生机构疾病管制与预防中心的报告，美国四分之一的成年人被医生诊断出患有关节炎，即约有 5,850 万人被诊断出患有关节炎。

对心血管健康的益处

阿斯匹灵具有抗血小板特性，因其降低心臟病和中风等心血管事件风险的能力而受到广泛认可。这种药物的作用是抑制血栓的形成，这是预防血管阻塞的关键因素，血管阻塞可能导致严重的心血管问题。医生经常开立阿斯匹灵作为有心血管疾病史或高危险群的预防措施。此外，阿斯匹灵对于治疗心肌梗塞等急性疾病也有效，进一步凸显了阿斯匹灵在心血管治疗中的重要性。随着人们对预防性医疗保健的重要性以及阿斯匹灵在降低心血管风险方面的作用的认识不断增强，阿斯匹灵的需求继续受到其既定的挽救生命的心血管健康益处的推动。

提高对潜在副作用的认知

随着有关阿斯匹灵副作用的资讯越来越广泛，医疗保健专业人员和消费者在使用阿斯匹灵时变得更加谨慎。溃疡和出血等胃肠道併发症的风险是众所周知的问题。这种认知的提高促使医疗保健专业人员更加谨慎地开药，并考虑具有更有利副作用的替代药物。然而，患者越来越意识到潜在的风险，这影响了他们使用阿斯匹灵的意愿，尤其是长期使用。

世界高龄化

全球老年人数量不断增加，与老龄化相关的健康状况，特别是心血管疾病的盛行率很高。阿斯匹灵因其对心血管系统的影响而闻名，通常为老年人开处方，以预防心臟病和中风。老年人发生血栓事件的风险往往增加，这使得阿斯匹灵成为医疗保健的重要组成部分。此外，随着年龄的增长，他们变得更容易受到疼痛和发炎相关病症的影响，进一步增加了对阿斯匹灵作为镇痛和发炎药物的需求。

出血风险

阿斯匹灵的抗凝血作用对于预防心血管事件很重要，但也会增加出血併发症的风险。这种担忧对于接受外科手术的患者或有出血性疾病病史的患者尤其重要。医疗保健专业人员在开处方时必须仔细考虑阿斯匹灵的益处和潜在副作用之间的微妙平衡。然而，对出血事件的恐惧可能会阻止服用阿斯匹灵，特别是在必须仔细评估风险效益比的某些患者群体中。

COVID-19 的影响：

人们越来越认识到 COVID-19 患者可能出现心血管併发症，导致作为预防措施的阿斯匹灵处方量激增。由于阿斯匹灵具有抗血小板作用，因此人们通常认为它在降低与重症 COVID-19 病例相关的血栓事件风险方面具有潜在作用。然而，大流行期间医疗保健服务的中断、患者优先事项的转变以及处方模式的转变正在影响全球市场。

Ecotrin 预计将在预测期内成为最大的细分市场

Ecotrin 部门由于专注于肠溶阿斯匹灵製剂，在预测期内占据阿斯匹灵製剂的最大全球市场占有率。 Ecotrin 是一个以其肠溶阿斯匹灵配方而闻名的品牌，该配方解决了通常与阿斯匹灵使用相关的胃肠道副作用问题。此外，肠溶衣可以让阿斯匹灵通过胃而不会引起刺激，从而在肠道中释放药物并被吸收。这项创新技术降低了胃溃疡和出血的风险，并提高了需要长期阿斯匹灵治疗的患者的药物耐受性。

咀嚼片预计在预测期内复合年增长率最高。

随着市场对患者便利性和用药医嘱遵从性的要求不断提高，咀嚼片提供了比传统锭剂更偏好、更容易使用的替代品。这项创新对吞嚥锭剂有困难的人很有吸引力，例如老人和儿童。咀嚼片细分市场利用了对更方便、更愉快的给药体验的需求，有助于提高患者的依从性。此外，阿斯匹灵咀嚼片的宜人味道使其成为寻求非处方止痛药的人的首选。

占比最高的地区

由于人们对心血管健康的认识不断提高、慢性病的迅速增加以及高龄化的加剧，预计亚太地区将在预测期内占据最大的市场占有率。随着该地区国家经历经济发展和都市化，生活方式也在不断变化，导致久坐习惯增加和饮食习惯改变，引发健康问题。作为一个额外的好处，心血管疾病的盛行率不断增加以及人们对阿斯匹灵预防功效的了解不断增加，正在推动对该药物的需求增加。

复合年增长率最高的地区：

欧洲高龄化和心血管疾病的高盛行率增加了对阿斯匹灵预防心臟病和中风的需求。该地区强调实证医学，强大的法律规范支持阿斯匹灵在各种临床环境中的持续处方和使用。此外，由于心血管健康仍然是欧洲医疗保健系统的主要关注点，阿斯匹灵作为一种具有成本效益且广泛使用的药物的作用预计将增加该地区对心血管疾病管理和预防的贡献。承诺，我们正在为该地区阿斯匹灵市场的繁荣做出重大贡献。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球阿斯匹灵药品市场：副产品

  • 生态素
  • 缓衝素
  • 非专利阿斯匹林
  • 其他产品

第六章全球阿斯匹灵药品市场：依剂型分类

  • 肠溶片
  • 咀嚼片
  • 可溶锭剂或发泡
  • 其他剂型

第七章全球阿斯匹灵药品市场：依配销通路

  • 药局/药局
  • 网路零售商
  • 杂货店和超级市场
  • 批发商
  • 其他配销通路

第八章全球阿斯匹灵药品市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • Cadila Healthcare Limited
  • Alembic Pharmaceuticals Limited
  • GlaxoSmithKline Consumer Healthcare Ltd
  • Takeda Pharmaceutical Company Limited
  • Torrent Pharmaceuticals Ltd
  • Abbott Laboratories
  • Aspen Pharmacare Holdings Limited
  • Dr. Reddy's Laboratories Ltd
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Novartis International AG
  • Pfizer Inc
  • Bayer AG
  • Roche Holding AG
Product Code: SMRC24714

According to Stratistics MRC, the Global Aspirin Drug Market is accounted for $2.5 billion in 2023 and is expected to reach $3.6 billion by 2030 growing at a CAGR of 5.4% during the forecast period. The aspirin drug market encompasses pharmaceutical products containing acetylsalicylic acid, commonly known as aspirin, which is a widely used medication with analgesic, anti-inflammatory, and antipyretic properties. Aspirin belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) and is utilized for pain relief, reduction of inflammation, and fever management. Additionally, aspirin is recognized for its anticoagulant effects, contributing to its application in preventing cardiovascular events such as heart attacks and strokes.

According to a report shared by the Centers for Disease Control and Prevention, a US-based national public health agency, 1 in 4 adults in the US were suffering from doctor-diagnosed arthritis, which is almost 58.5 million people.

Market Dynamics:

Driver:

Cardiovascular health benefits

Aspirin, with its antiplatelet properties, is widely recognized for its ability to reduce the risk of cardiovascular events, including heart attacks and strokes. The drug works by inhibiting the formation of blood clots, a crucial factor in preventing blockages in blood vessels that can lead to severe cardiovascular issues. Physicians often prescribe aspirin as a preventive measure for individuals with a history of cardiovascular diseases or those at higher risk. Additionally, the drug's efficacy in managing acute conditions, such as myocardial infarction, further underscores its importance in cardiovascular care. As awareness grows regarding the significance of preventive healthcare and the role of aspirin in reducing cardiovascular risks, the demand for aspirin continues to be driven by its well-established and life-saving cardiovascular health benefits.

Restraint:

Growing awareness of potential side effects

As information about the adverse effects associated with aspirin becomes more widely disseminated, both healthcare professionals and consumers exercise increased caution in its usage. The risk of gastrointestinal complications, such as ulcers and bleeding, is a well-documented concern. This heightened awareness has led to more prudent prescribing practices by healthcare providers, who may consider alternative medications with a more favorable side effect profile. However, patients are becoming more informed about the potential risks, impacting their willingness to use aspirin, particularly for long-term applications.

Opportunity:

Global aging population

With an increasing number of elderly individuals worldwide, there is a higher prevalence of age-related health conditions, particularly cardiovascular diseases. Aspirin, known for its cardiovascular benefits, is commonly prescribed to the aging demographic as a preventive measure against heart attacks and strokes. The elderly population often experiences a higher risk of thrombotic events, making aspirin a key component in their healthcare regimen. Additionally, as people age, they may be more susceptible to conditions associated with pain and inflammation, further contributing to the demand for aspirin as an analgesic and anti-inflammatory medication.

Threat:

Risk of bleeding

While aspirin's anticoagulant properties are crucial for preventing cardiovascular events, they concurrently elevate the risk of bleeding complications. This concern is particularly relevant for individuals undergoing surgical procedures or those with pre-existing bleeding disorders. The delicate balance between aspirin's benefits and potential adverse effects requires careful consideration by healthcare professionals when prescribing the drug. However, the fear of bleeding events may lead to hesitancy in prescribing aspirin, especially in certain patient populations where the risk-benefit ratio must be meticulously assessed.

COVID-19 Impact:

The increased awareness of potential cardiovascular complications in COVID-19 patients has led to a surge in aspirin prescriptions as a preventive measure. As aspirin exhibits antiplatelet properties, it is often considered for its potential role in mitigating the risk of thrombotic events associated with severe COVID-19 cases. However, disruptions in healthcare services, shifts in patient priorities, and altered prescribing patterns during the pandemic have influenced the market globally.

The ecotrin segment is expected to be the largest during the forecast period

Ecotrin segment commanded the largest market share of aspirin drug globally over the projected period due to its focus on enteric-coated aspirin formulations. Ecotrin, a brand recognized for its enteric-coated aspirin products, addresses the issue of gastrointestinal side effects commonly associated with aspirin use. Furthermore, the enteric coating enables the aspirin to pass through the stomach without causing irritation, releasing the medication in the intestines where absorption occurs. This innovation reduces the risk of stomach ulcers and bleeding, enhancing the drug's tolerability for patients requiring long-term aspirin therapy.

The chewable tablets segment is expected to have the highest CAGR during the forecast period

With a growing market trend toward patient convenience and adherence, chewable aspirin tablets offer a more palatable and user-friendly alternative to traditional pill forms. This innovation appeals to individuals who may have difficulty swallowing pills, including the elderly and children. The Chewable Tablets segment is capitalizing on the demand for a more accessible and enjoyable medication experience, contributing to increased patient compliance. Furthermore, the pleasant taste of chewable aspirin tablets makes them a favorable choice for individuals seeking over-the-counter pain relief options.

Region with largest share:

Due to the rising awareness of cardiovascular health, a surge in chronic diseases, and an expanding aging population, Asia Pacific region is expected to hold largest market share over the forecast period. As countries in the region undergo economic development and urbanization, lifestyles are evolving, leading to an increase in sedentary habits and dietary changes that contribute to health concerns. Additionally, the growing prevalence of cardiovascular diseases in tandem with an increasing understanding of aspirin's preventive benefits is fostering a higher demand for this medication.

Region with highest CAGR:

Europe is expected to hold profitable growth owing to the region's aging population, coupled with a high prevalence of cardiovascular diseases, has propelled the demand for aspirin as a preventive measure against heart attacks and strokes. The region's emphasis on evidence-based medicine and a strong regulatory framework supports the continued prescription and use of aspirin in various clinical contexts. Additionally, as cardiovascular health remains a primary focus in European healthcare systems, aspirin's role as a cost-effective and widely available medication aligns with the region's commitment to managing and preventing cardiovascular diseases, thereby contributing significantly to the flourishing aspirin drug market in the region.

Key players in the market:

Some of the key players in Aspirin Drug market include Cadila Healthcare Limited, Alembic Pharmaceuticals Limited, GlaxoSmithKline Consumer Healthcare Ltd, Takeda Pharmaceutical Company Limited, Torrent Pharmaceuticals Ltd, Abbott Laboratories, Aspen Pharmacare Holdings Limited, Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Novartis International AG, Pfizer Inc, Bayer AG and Roche Holding AG.

Key Developments:

In December 2023, Zydus Worldwide DMCC, a wholly-owned subsidiary of Zydus Lifesciences Ltd and Daewoong Pharmaceutical Co Ltd, has entered into a licensing agreement to co-develop and commercialise Leuprolide Acetate for Depot Suspension in six dosage strengths for the United States (US) market, the company in a regulatory filing with the BSE. The terms of the agreement will result in Zydus assuming full responsibility for the clinical development and commercialisation in the US market. Daewoong, on the other hand, will be responsible for the pre-clinical studies, production, and supply of the product.

In March 2023, Ahmedabad-based Cadila Pharmaceuticals has signed a Memorandum of Understanding (MoU) with the government of Gujarat to invest Rs 1,000 crore in different existing projects. The MoU was signed in Gandhinagar between Industries Commissioner Rahul Gupta on behalf of the government of Gujarat and Cadila Pharmaceuticals COO, Mitul Dave, under the Government of Gujarat's "Atma Nirbhar Gujarat Schemes for Assistance to Industries".

Products Covered:

  • Ecotrin
  • Bufferin
  • Generic Aspirin
  • Other Products

Dosage Forms Covered:

  • Enteric-Coated Tablets
  • Chewable Tablets
  • Dissolvable or Effervescent Tablets
  • Other Dosage Forms

Distribution Channels Covered:

  • Pharmacies and Drugstores
  • Online Retailers
  • Grocery Stores and Supermarkets
  • Wholesale Distributors
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Aspirin Drug Market, By Product

  • 5.1 Introduction
  • 5.2 Ecotrin
  • 5.3 Bufferin
  • 5.4 Generic Aspirin
  • 5.5 Other Products

6 Global Aspirin Drug Market, By Dosage Form

  • 6.1 Introduction
  • 6.2 Enteric-Coated Tablets
  • 6.3 Chewable Tablets
  • 6.4 Dissolvable or Effervescent Tablets
  • 6.5 Other Dosage Forms

7 Global Aspirin Drug Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Pharmacies and Drugstores
  • 7.3 Online Retailers
  • 7.4 Grocery Stores and Supermarkets
  • 7.5 Wholesale Distributors
  • 7.6 Other Distribution Channels

8 Global Aspirin Drug Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Cadila Healthcare Limited
  • 10.2 Alembic Pharmaceuticals Limited
  • 10.3 GlaxoSmithKline Consumer Healthcare Ltd
  • 10.4 Takeda Pharmaceutical Company Limited
  • 10.5 Torrent Pharmaceuticals Ltd
  • 10.6 Abbott Laboratories
  • 10.7 Aspen Pharmacare Holdings Limited
  • 10.8 Dr. Reddy's Laboratories Ltd
  • 10.9 Sun Pharmaceutical Industries Ltd
  • 10.10 Teva Pharmaceutical Industries Ltd
  • 10.11 Novartis International AG
  • 10.12 Pfizer Inc
  • 10.13 Bayer AG
  • 10.14 Roche Holding AG

List of Tables

  • Table 1 Global Aspirin Drug Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
  • Table 4 Global Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
  • Table 5 Global Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
  • Table 6 Global Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 7 Global Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 8 Global Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
  • Table 9 Global Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
  • Table 10 Global Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
  • Table 11 Global Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 12 Global Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 13 Global Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
  • Table 14 Global Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
  • Table 15 Global Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
  • Table 16 Global Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
  • Table 17 Global Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 18 North America Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
  • Table 19 North America Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
  • Table 20 North America Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
  • Table 21 North America Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
  • Table 22 North America Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
  • Table 23 North America Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 24 North America Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 25 North America Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
  • Table 26 North America Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
  • Table 27 North America Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
  • Table 28 North America Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 29 North America Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 30 North America Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
  • Table 31 North America Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
  • Table 32 North America Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
  • Table 33 North America Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
  • Table 34 North America Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 35 Europe Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
  • Table 36 Europe Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
  • Table 37 Europe Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
  • Table 38 Europe Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
  • Table 39 Europe Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
  • Table 40 Europe Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 41 Europe Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 42 Europe Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
  • Table 43 Europe Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
  • Table 44 Europe Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
  • Table 45 Europe Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 46 Europe Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 47 Europe Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
  • Table 48 Europe Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
  • Table 49 Europe Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
  • Table 50 Europe Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
  • Table 51 Europe Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 52 Asia Pacific Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
  • Table 53 Asia Pacific Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
  • Table 54 Asia Pacific Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
  • Table 55 Asia Pacific Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
  • Table 56 Asia Pacific Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
  • Table 57 Asia Pacific Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 58 Asia Pacific Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 59 Asia Pacific Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
  • Table 60 Asia Pacific Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
  • Table 61 Asia Pacific Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
  • Table 62 Asia Pacific Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 63 Asia Pacific Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 64 Asia Pacific Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
  • Table 65 Asia Pacific Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
  • Table 66 Asia Pacific Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
  • Table 67 Asia Pacific Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
  • Table 68 Asia Pacific Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 69 South America Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
  • Table 70 South America Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
  • Table 71 South America Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
  • Table 72 South America Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
  • Table 73 South America Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
  • Table 74 South America Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 75 South America Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 76 South America Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
  • Table 77 South America Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
  • Table 78 South America Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
  • Table 79 South America Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 80 South America Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 81 South America Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
  • Table 82 South America Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
  • Table 83 South America Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
  • Table 84 South America Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
  • Table 85 South America Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 86 Middle East & Africa Aspirin Drug Market Outlook, By Country (2021-2030) ($MN)
  • Table 87 Middle East & Africa Aspirin Drug Market Outlook, By Product (2021-2030) ($MN)
  • Table 88 Middle East & Africa Aspirin Drug Market Outlook, By Ecotrin (2021-2030) ($MN)
  • Table 89 Middle East & Africa Aspirin Drug Market Outlook, By Bufferin (2021-2030) ($MN)
  • Table 90 Middle East & Africa Aspirin Drug Market Outlook, By Generic Aspirin (2021-2030) ($MN)
  • Table 91 Middle East & Africa Aspirin Drug Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 92 Middle East & Africa Aspirin Drug Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 93 Middle East & Africa Aspirin Drug Market Outlook, By Enteric-Coated Tablets (2021-2030) ($MN)
  • Table 94 Middle East & Africa Aspirin Drug Market Outlook, By Chewable Tablets (2021-2030) ($MN)
  • Table 95 Middle East & Africa Aspirin Drug Market Outlook, By Dissolvable or Effervescent Tablets (2021-2030) ($MN)
  • Table 96 Middle East & Africa Aspirin Drug Market Outlook, By Other Dosage Forms (2021-2030) ($MN)
  • Table 97 Middle East & Africa Aspirin Drug Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 98 Middle East & Africa Aspirin Drug Market Outlook, By Pharmacies and Drugstores (2021-2030) ($MN)
  • Table 99 Middle East & Africa Aspirin Drug Market Outlook, By Online Retailers (2021-2030) ($MN)
  • Table 100 Middle East & Africa Aspirin Drug Market Outlook, By Grocery Stores and Supermarkets (2021-2030) ($MN)
  • Table 101 Middle East & Africa Aspirin Drug Market Outlook, By Wholesale Distributors (2021-2030) ($MN)
  • Table 102 Middle East & Africa Aspirin Drug Market Outlook, By Other Distribution Channels (2021-2030) ($MN)